Investors

News

10/09/18
REDWOOD CITY, Calif. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective October 8, 2018 , the compensation committee of the company’s board of directors granted 65 new employees options to purchase an aggregate of 542,000 shares of the
Printer Friendly Version
09/25/18
REDWOOD CITY, Calif. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the European Commission (EC) has granted marketing authorization to UDENYCA™ (formerly CHS-1701), a pegfilgrastim (Neulasta®) biosimilar.
Printer Friendly Version
09/21/18
REDWOOD CITY, Calif. , Sept. 21, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective September 20, 2018 , the compensation committee of the company’s board of directors granted 6 new employees and a Vice President, Corporate Communications and Public
Printer Friendly Version
09/17/18
REDWOOD CITY, Calif. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will be presenting at the 2018 Cantor Global Healthcare Conference being held in New York on Tuesday, October 2, 2018 at 8:00 am ET .
Printer Friendly Version
08/20/18
REDWOOD CITY, Calif. , Aug. 20, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will participate in two upcoming investor healthcare conferences in September. Management participation in a fireside chat is scheduled at Baird’s 2018 Global
Printer Friendly Version
08/17/18
REDWOOD CITY, Calif. , Aug. 17, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective August 14, 2018 , the company’s board of directors granted 3 new employees options to purchase an aggregate of 35,500 shares of the company’s common stock with a per
Printer Friendly Version
08/08/18
REDWOOD CITY, Calif. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter ended June 30 , 2018.   Second Quarter 2018 Corporate Highlights Include: UDENYCA™ (pegfilgrastim-cbqv), biosimilar
Printer Friendly Version
07/27/18
REDWOOD CITY, Calif. , July 27, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of UDENYCA™ (formerly
Printer Friendly Version
07/25/18
REDWOOD CITY, Calif. , July 25, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective July 19, 2018 , the compensation committee of the company’s board of directors granted 11 new employees options to purchase an aggregate of 167,500 shares of the
Printer Friendly Version
07/24/18
REDWOOD CITY, Calif. , July 24, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its second quarter 2018 financial results will be released after market close on Wednesday, August 8 , 2018.  Starting at 4:30 p.m. ET , Coherus’ management will host a conference
Printer Friendly Version
06/22/18

REDWOOD CITY, Calif. , June 22, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective June 21, 2018 , the compensation committee of the company’s board of directors granted 8 new employees options to purchase an aggregate of 142,000 shares of the company’s

Printer Friendly Version
05/25/18
REDWOOD CITY, Calif. , May 25, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective May 23, 2018 , the compensation committee of the company’s board of directors granted 4 new employees options to purchase an aggregate of 61,000 shares of the company’s
Printer Friendly Version
05/22/18
REDWOOD CITY, Calif. , May 22, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced the pricing of its underwritten public offering of 5,172,413 shares of its common stock at a price to the public of $14.50 per share. All of the shares of the common stock to be sold in
Printer Friendly Version
05/21/18
REDWOOD CITY, Calif. , May 21, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced it has commenced an underwritten public offering of $75,000,000 of shares of its common stock. All of the shares of the common stock to be sold in the offering will be offered by
Printer Friendly Version
05/14/18
REDWOOD CITY, Calif. , May 14, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced the U.S. Food and Drug Administration ( FDA ) has accepted and acknowledged for review the re-submission of the biologics license application (BLA) for CHS-1701, a pegfilgrastim
Printer Friendly Version
05/10/18
REDWOOD CITY, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today reviewed corporate highlights and reported financial results for the quarter ended March 31 , 2018.   First Quarter 2018 Corporate Highlights Include: Oncology therapeutic franchise: CHS-1701
Printer Friendly Version
05/10/18
REDWOOD CITY, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced the appointment of Samuel Nussbaum , M.D. to its Board of Directors.   “We are thrilled to have a health care policy and payer expert of Dr.
Printer Friendly Version
05/03/18
REDWOOD CITY, Calif. , May 03, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced the re-submission of its biologics license application (BLA) for CHS-1701, a pegfilgrastim (Neulasta®) biosimilar candidate, to the U.S. FDA under the 351(k) pathway.
Printer Friendly Version
05/01/18
REDWOOD CITY, Calif. , May 01, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will be presenting at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018 at 11:40 am ET being held in Las Vegas, Nevada .
Printer Friendly Version
04/24/18
REDWOOD CITY, Calif. , April 24, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its first quarter 2018 financial results will be released after market close on Thursday, May 10 , 2018.  Starting at 4:30 p.m. EDT , Coherus’ management will host a conference
Printer Friendly Version
04/19/18
REDWOOD CITY, Calif. , April 19, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective April 19, 2018 , the compensation committee of the company’s board of directors granted 9 new employees options to purchase an aggregate of 187,000 shares of the
Printer Friendly Version
04/02/18
REDWOOD CITY, Calif. , April 02, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will be presenting at the H.C. Wainwright Annual Life Sciences Conference on Tuesday, April 10, 2018 at 8:10 am ET being held in Monte Carlo, Monaco .
Printer Friendly Version
03/13/18
REDWOOD CITY, Calif. , March 13, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective March 12, 2018 , the compensation committee of the company’s board of directors granted 2 new employees options to purchase an aggregate of 37,000 shares of the
Printer Friendly Version
03/08/18
REDWOOD CITY, Calif. , March 08, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today reviewed corporate events and reported financial results for the quarter and full year ended December 31 , 2017.   Fourth Quarter and Full Year 2017 Financial Results: Research and development
Printer Friendly Version
03/01/18
REDWOOD CITY, Calif. , March 01, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will present at two upcoming investor healthcare conferences. Management participation in a fireside chat at the 38 th Cowen & Company Healthcare Conference on
Printer Friendly Version
02/27/18
REDWOOD CITY, Calif. , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its fourth quarter and full year 2017 financial results will be released after market close on Thursday, March 8 , 2018.  At 4:30 p.m.
Printer Friendly Version
01/02/18
REDWOOD CITY, Calif. , Jan. 02, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at the 36 th annual J.P. Morgan healthcare conference on Monday, January 8, 2017 at 2:00 p.m. PT being held in San Francisco .
Printer Friendly Version